New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study

Overview

Journal Risk Manag Healthc Policy

Publisher Dove Medical Press

Specialty Public Health

Date 2024 Sep 23

PMID 39309121

Authors

Xingyuan Gao

Man Yu

Yuyang Sun

Tiansi Zhang

Xin Li

Lingli Zhang

Changqing Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: The increasing global burden of cancer has become a significant challenge for public health. The Chinese government introduced the National Drug Price Negotiation (NDPN) policy with the goal of lowering the prices of innovative drugs and enhancing their accessibility. This study aims to evaluate the impact of the 2021 NDPN policy on the availability, utilization, and cost of anticancer medicines in China.

Methods: Data was gathered from 1519 hospitals between April 2021 and December 2022, with a focus on eight anticancer drugs affected by the 2021 NDPN policy. The availability, Defined Daily Doses (DDDs), and cost per Defined Daily Dose (DDDc) before and after the intervention were evaluated through interrupted time series analysis.

Results: The NDPN policy resulted in a substantial 5.10% increase in the availability of anticancer drugs (p < 0.001). Utilization also experienced a significant surge, with an immediate increase of 11,254.36 DDDs (p < 0.001) and a monthly increase of 1208.28 DDDs (p < 0.001) following policy implementation. The DDDc decreased by US$ 111.00 (p < 0.001) immediately after the policy. Disparities in regional drug utilization were evident, with higher usage in the eastern region.

Conclusion: The 2021 NDPN policy has notably enhanced the availability and utilization of anticancer medications in China while reducing their cost, in line with the policy's objectives. However, continuous monitoring is essential to ensure sustained access and to tackle regional disparities in drug utilization.

References

Li H, Liu G, Wu J, Wu J, Dong C, Hu S . Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions. Value Health Reg Issues. 2018; 15:133-137. DOI: 10.1016/j.vhri.2018.01.009. View

Hong D, Lv D, Wu J, Li X, Zhao Q, Lu X . The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis. Risk Manag Healthc Policy. 2023; 16:1781-1790. PMC: 10497050. DOI: 10.2147/RMHP.S418541. View

Sun Y, Zhu Z, Zhang J, Han P, Qi Y, Wang X . Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis. Int J Environ Res Public Health. 2022; 19(8). PMC: 9025142. DOI: 10.3390/ijerph19084578. View

Huang C, Ung C, Wushouer H, Bai L, Li X, Guan X . Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis. Int J Health Policy Manag. 2021; 11(8):1489-1495. PMC: 9808358. DOI: 10.34172/ijhpm.2021.47. View

Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R . Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4(1):47-53. PMC: 11256708. DOI: 10.1016/j.jncc.2024.01.006. View

Bonetti A, Giuliani J . Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021; 3:100060. PMC: 8454721. DOI: 10.1016/j.lanepe.2021.100060. View

McMaughan D, Oloruntoba O, Smith M . Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging. Front Public Health. 2020; 8:231. PMC: 7314918. DOI: 10.3389/fpubh.2020.00231. View

Zhang T, Lu B, Yan Z, Huang X, Lu W . Impacts of a New Episode-Based Payment Scheme on Volume, Expenditures, and Efficiency in Public Hospitals: A Quasi-Experimental Interrupted Time-Series Study in Jinhua, China. Risk Manag Healthc Policy. 2022; 15:1659-1669. PMC: 9462945. DOI: 10.2147/RMHP.S376516. View

. Global cancer burden growing, amidst mounting need for services. Saudi Med J. 2024; 45(3):326-327. PMC: 11115397. View

10.

Hategeka C, Ruton H, Karamouzian M, Lynd L, Law M . Use of interrupted time series methods in the evaluation of health system quality improvement interventions: a methodological systematic review. BMJ Glob Health. 2020; 5(10). PMC: 7559052. DOI: 10.1136/bmjgh-2020-003567. View

11.

Shih Y, Xu Y, Liu L, Smieliauskas F . Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. J Clin Oncol. 2017; 35(22):2482-2489. PMC: 5536165. DOI: 10.1200/JCO.2017.72.3742. View

12.

Linden A . A matching framework to improve causal inference in interrupted time-series analysis. J Eval Clin Pract. 2017; 24(2):408-415. DOI: 10.1111/jep.12874. View

13.

Zhang Y, Wushouer H, Han S, Fu M, Guan X, Shi L . The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health. 2021; 6(7). PMC: 8286756. DOI: 10.1136/bmjgh-2021-006196. View

14.

Su M, Lao J, Zhang N, Wang J, Anderson R, Sun X . Financial hardship in Chinese cancer survivors. Cancer. 2020; 126(14):3312-3321. DOI: 10.1002/cncr.32943. View

15.

Diao Y, Qian J, Liu Y, Zhou Y, Wang Y, Ma H . How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. J Glob Health. 2019; 9(2):020702. PMC: 6815654. DOI: 10.7189/jogh.09.020702. View

16.

Cai L, Tao T, Li H, Zhang Z, Zhang L, Li X . Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study. J Glob Health. 2022; 12:11016. PMC: 9758701. DOI: 10.7189/jogh.12.11016. View

17.

Fang W, Xu X, Zhu Y, Dai H, Shang L, Li X . Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study. Front Public Health. 2021; 9:714127. PMC: 8377668. DOI: 10.3389/fpubh.2021.714127. View